

PALM BEACH COUNTY BOARD OF COUNTY COMMISSIONERS SITTING AS THE ENVIRONMENTAL CONTROL BOARD

BOARD APPOINTMENT SUMMARY

	BOARD AFFOIR	TIMENT SUMMART	
Meeting Date:	October 22, 2024		
Department:	Florida Department	of Health in Palm Beach	County
Submitted by:	Legal Department		
Advisory Board Name:	Environmental Cont	rol Hearing Board	
	I. EXECU	JTIVE BRIEF	
			nt of one (1) member to the eginning November 19, 2024 to
NOMINEE:	SEAT #:	REQUIREMENT:	NOMINATED BY
Larry M. Bush, MD, FACP, FID	OSA 2	Medical Doctor	PBC Medical Society
of the Florida Engineering So replacing Dr. Shulan, who is to 0; Hispanic-American: 1 (20% Dr. Bush is a Caucasian male. The applicant for appointment County Medical Society. Background and Justification	ciety, and two (2) citize rm limited. The current and Asian-American: Countywide (HH) to Seat # 2, Larry M. Bu n: Chapter 77-616, Law	ens-at-large not holding endiversity count is: Caucas 1 (20%). The current gerush is a Medical Doctor recessor of Florida, as amended,	the Palm Beach County Chapter lective office. Dr. Bush will be sian: 2 (40%); African-American: nder ratio (female: male) is 2:2. commended by the Palm Beach provides for the organization of sist of an attorney, a doctor, an
engineer, and two citizens of P for the members of the Environ	'alm Beach County. Pal	lm Beach County Resoluti	on 92-123 establishes the terms
Attachments:			
Curriculum Vitae of La	lication for Larry M. Bus rry M. Bush, MD er-PBC Medical Society		
Recommended by:	M.D., Director, De	partment of Health,PBC	10\01\2024 Date

Legal Sufficiency:



PALM BEACH COUNTY BOARD OF COUNTY COMMISSIONERS ENVIRONMENTAL CONTROL HEARING BOARD

I. AUTHORITY:

PBC Environmental Control Act, Chapter 77-616, Section 9, Laws of Florida, Ordinance No. 78-5; as amended by Ordinance No. 79-15; amended by Ordinance No. 85-25; as amended by Ordinance No. 87-22. Unified Land Development Code, Section 4.12, amended by Resolution No. R92-123.

II. APPOINTING BODY:

Board of County Commissioners

III. COMPOSITION, QUALIFICATIONS, TERMS & REMOVAL:

The Board shall be composed of five (5) members. Membership shall consist of one (1) lawyer, recommended by the PBC Bar Association; one (1) medical doctor, recommended by the PBC Medical Society; one (1) engineer, recommended by the PBC chapter of the Florida Engineering Society; and two (2) citizens at-large. The term of appointments shall be for three (3) years. Appointments to fill any vacancy on the Hearing Board shall be for the remainder of the unexpired term of office. Members shall receive no compensation for their services. Travel reimbursements are limited to expenses incurred only for travel outside PBC necessary to fulfill the responsibilities of membership of the Board.

EXTENDED COMPOSITION:

IV. MEETINGS:

Every forty-five (45) days at 8:30a.m., 800 Clematis, West Palm Beach, FL

V. FUNCTIONS:

To hear and conduct hearings into the merits of alleged violations to sections promulgated under Chapter 77-616, Special Act, Laws of Florida, and PBC Ordinance No. 78-5, as amended, and to issue injunctive and affirmative relief for violations; and after due public hearing upholding a violation, to reach a decision setting forth such findings of fact and conclusions of law as are required in view of the issues presented. The decision shall contain an order which may be framed in the manner of a writerior of injunction requiring the violator to conform with either or all of the following requirements: (a) to refrain from committing, creating, maintaining, or permitting the violations; (b) to take such affirmative action as the ECHB deems necessary and reasonable under the circumstances to correct such violation; (c) to issue orders imposing civil penalties of up to \$500 for each day of violation; (d) to issue subpoenas to command the appearance of any person before a hearing at a specified time and place to be examined as a witness. Such subpoenas may require such person to produce all books, papers and documents in that person's possession or under that person's control, material to such hearings; and (e) to administer oaths to any or all persons who are to testify before the ECHB.

indicates a member having an action pending

VI. LIAISON INFORMATION:

LIAISON DEPARTMENT

CONTACT PERSON

Florida Dept. of Health - Palm Beach C Barbara Sullivan

800 Clematis St

ADDRESS

West Palm Beach FL 33401

Phone # 561-671-4115

^{*} indicates a member having an action pending

ENVIRONMENTAL CONTROL HEARING BOARD

SEAT ID	CURRENT MEMBER	ROLE TYPE	RACE CODE	GENDER	BUSINESS / HOME PHONE	SEAT REQUIREMENT	APPOINT DATE	REAPPOINT DATE	EXPIRE DATE
Appointed	By : At-Large/Palm Beach C	ounty Boar	d of Cou	nty Comm	issioners				
	Gary Betensky gbetensky@daypitney.com Day Pitney, LLP 250 Australian Ave S Ste 15 West Palm Beach FL 33401	Member	CA	M	954-805-3087	Attorney	01/24/2023		01/23/2026
	NOMINATED BY	:Palm Bead	ch County	/ Bar Assoc	iation				
	David Shulan ragweed@msn.com	Member	CA	M	518-852-9387	Medical Doctor/ER Physician	11/20/2018	11/16/2021	11/18/2024
	12264 Bear River Rd Boynton Beach FL 33473								
	NOMINATED BY	:Palm Bead	ch County	/ Medical S	ociety				
	Vivian A Demille vivian_demille@yahoo.com	Member	CA	F	561-762-9622.	Resident of Palm Beach County	08/17/2021		01/23/2026
	2753 Hampton Cir S Delray Beach FL 33444								
	NOMINATED BY	:							
	Douglas H. MacLaughlin douglasmaclaughlin@aol.con	Member n	CA	М	561-329-4403	Resident of Palm Beach County	01/14/2020	01/24/2023	01/23/2026
	319 Greenwood Dr West Palm Beach FL 33405								
	NOMINATED BY	:							
* indicates	s a member having an action _l	pending	•						
ABC_Speci	ficsBoardComp_Members.rpt				Page	3 of 4			10/1/2024

Appointed By : At-Large/Palm Beach County Board of County Commissioners

5

Toral Hertzberg Member AS F 561--79-1-4148 Engineer thertzberg@wellingtonfl.gov Village of Wellington 12300 Forest Hill Blvd West Palm Beach FL 33414

NOMINATED BY: Florida Engineering Society - PBC Chapter

ABC_SpecificsBoardComp_Members.rpt

02/10/2026

02/11/2023

^{*} indicates a member having an action pending

PALM BEACH COUNTY BOARD OF COUNTY COMMISSIONERS BOARDS/COMMITTEES APPLICATION

The information provided on this form will be used in considering your nomination. Please COMPLETE SECTION II IN FULL. Answer "none" or "not applicable" where appropriate. Please attach a biography or résumé to this form.

ection I (Departm	ent): (Please	Print)					
Board Name: _	Environmen	tal Control Hear	ing Board	-	<u> </u>	Advisory []	Not Advisory [X]
[X] At Lar	ge Appointme	nt	or []	District Appointn	nent /Dist	rict #:	
Term of Appointm	ent: 3	Years.	From:	11-19-25	<u> </u>	To:	8-27
Seat Requirement:	Medic	al Doctor recomn	nended by the	PBC Medical So	ciety	Seat #:	2
[]*Reappo	ointment		or	[X] New A	Appointme	ent	
or [] to co		m of		Due to:		resignation	[] other
erm shall be consi ection II (Applica	dered by the int): (Please I	Board of County	Commissione	rs:	disclose	d voting conflic	ts during the previo
PPLICANT, UNL		TED, MUST BE	<i>A COUNTY R</i> LAR			MARC	
	BUSH Last		First	KI		Middle	
Occupation/Affilia	* **	MEDICAL PHYS	<u>ICIAN – INFE</u>	CTIOUS DISEAS	SES and I	NTERNAL ME	DICINE
		Owner [X]		Employee []		Office	r []
Business Name:		COMPREHENSIV	/E INFECTIO	US DISEASE, LL	<u>C</u>		
Business Address	<u>.</u>	5401 SOUTH CO	NGRESS AVE	NUE, SUITE 20	<u> </u>	<u> </u>	
City & State	<u> </u>	ATLANTIS, FLO	RIDA		Zip Code:	33462	<u> </u>
Residence Addre	ss:	205 AVILA ROA	D	······································		<u> </u>	
City & State	· .	WEST PALM BE	ACH, FLORID	Α	Zip Code:	_33405	
Home Phone:	(56	61)762-1634	В	usiness Phone:	(561) 967-0101	Ext.
Cell Phone:	(561)762-1634	F	ax:	(56	1)967-6240	<u> </u>
Email Address:	DRL	ARRY561@AOL.	СОМ	-			
failing Address Pr	eference: [Business [X]	Residence				
lave you ever been f Yes, state the cou	n convicted of art, nature of o	a felony: Yes offense, disposition	No n of case and da	XXXXte:			
Minority Identific		[X] Male [] Hispanic-A] Female] Asian-American	ı []A	frican-American	n [X] Caucasian

Section II Continued:

CONTRACTUAL RELATIONSHIPS: Pursuant to Article XIII, Sec. 2-443 of the Palm Beach County Code of Ethics, advisory board members are prohibited from entering into any contract or other transaction for goods or services with Palm Beach County. Exceptions to this prohibition include awards made under sealed competitive bids, certain emergency and sole source purchases, and transactions that do not exceed \$500 per year in aggregate. These exemptions are described in the Code. This prohibition does not apply when the advisory board member's board provides no regulation, oversight, management, or policy-setting recommendations regarding the subject contract or transaction and the contract or transaction is disclosed at a public meeting of the Board of County Commissioners. To determine compliance with this provision, it is necessary that you, as a board member applicant, identify all contractual relationships between Palm Beach County government and you as an individual, directly or indirectly, or your employer or business. This information should be provided in the space below. If there are no contracts or transactions to report, please verify that none exist. Staff will review this information and determine if you are eligible to serve or if you may be eligible for an exception or waiver pursuant to the code.

PRINCIPLE AND ARTS	Department/Division	Description of Services	Term
Contract/Transaction No. Example: (R#XX-XX/PO XX)	Parks & Recreation	General Maintenance	10/01/00-09/30/2100
			<u></u>
	(Attach Additional She	et(s), if necessary)	And the second s
NONE	X	NOT APPLICABLE/ (Governmental Entity)	3
Ethics and read the State Guide	I members are required to read and co to the Sunshine Amendment, Article styethics.com/training.htm. Ethics and upon reappointment.	XIII, and the training requires	nent can be found on the web
By signing below I ackno Code of Ethics, and I hav	wledge that I have read, understan re received the required Ethics train	d, and agree to abide by Article ning (in the manner checked be	XIII, the Palm Beach County low):
X By wa	atching the training program on the W ending a live presentation given on	eb, DVD or VHS onSEPT.	2520_24
	AND	!	
& State of Florida Code	wledge that I have read, understand of Ethics:		
*Applicant's Signature: Printed Name: LARRY BUSH M	LRUL US Dat	re: SEPT. 25, 2024	secondaria.
Any questions and/or concerns re	garding Article XIII, the Palm Beach thics.com or contact us via email at e	County Code of Ethics, please vi	isit the Commission on Ethics
Ba	Return this Forbara Sullivan, Florida Departmen 800 Clematis Street, Rm 549, W	nt of Health Palm Beach County	,
Section III (Commissioner, if a Appointment to be made	pplicable): at BCC Meeting on:		
Commissioner's Signature:		Date:	<u> </u>
Pursuant to Florida's Public Records Lav	y, this document may be reviewed and photoco	pied by members of the public.	Revised 02/01/2016
Page 2 of 2			

LARRY M. BUSH, MD, FACP, FIDSA

(Last Revision: July, 2024)

Comprehensive Infectious Diseases, LLC.

5401 South Congress Avenue

Suite 201

Atlantis, Florida 33462 Telephone: 561-967-0101

Fax: 561-967-6260

E-mail: drlarry561@aol.com

EDUCATION

1969 BA, Central High School

Philadelphia, Pennsylvania

1973 BA, The University of Pennsylvania

Philadelphia, Pennsylvania

MD, The Medical College of Pennsylvania

Philadelphia, Pennsylvania

POSTGRADUATE TRAINING

1982-83 Internship, Internal Medicine

Pennsylvania Hospital

University of Pennsylvania Health System

Philadelphia, Pennsylvania

1983-85 Residency, Internal Medicine

Pennsylvania Hospital

University of Pennsylvania Health System

Philadelphia, Pennsylvania

1984-85 Chief Medical Resident

Pennsylvania Hospital

University of Pennsylvania Health System

Philadelphia, Pennsylvania

1986-88 Fellowship

Infectious Diseases

The Medical College of Pennsylvania

Philadelphia, Pennsylvania

MEDICAL LICENSURE

July 1983 Pennsylvania (active) MD029186E

June 1987 New Jersey (inactive) MD49907

June 1989 Florida (active) ME55230

BOARD CERTIFICATION

1982 Diplomat, National Board of Medicine

1985 Diplomat, American Board of Internal Medicine

1988 Diplomat, American Board of Internal Medicine

Subspecialty, Infectious Diseases

FACULTY APPOINTMENTS

1983-84 Assistant Instructor in Medicine

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania

1984-85 Instructor in Medicine

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania

1985-86 Clinical Associate in Medicine

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania

1985-86 Staff Physician

Department of Emergency Room Medicine

Pennsylvania Hospital Philadelphia, Pennsylvania

1987-88 Instructor in Medicine

The Medical College of Pennsylvania

Philadelphia, Pennsylvania

1988-90 Clinical Assistant Professor

The Medical College of Pennsylvania

Philadelphia, Pennsylvania

1991-98 Clinical Assistant (voluntary) Professor Department of Medicine Southeastern University of the Health Sciences North Miami Beach, Florida 2004-10 Clinical Associate Professor of Medicine Department of Biomedical Science Charles E. Schmidt College of Science Florida Atlantic University Boca Raton, Florida Clinical Associate (voluntary) Professor of Medicine 2004-10 University of Miami-Miller School of Medicine Miami, Florida 2008 -15 Educational Director, Infectious Diseases University of Miami-Miller School of Medicine affiliated Internal Medicine Residency Program Palm Beach County, Florida Affiliate Associate Professor of Medicine 2010 -Department of Education University of Miami-Miller School of Medicine/Palm Beach County, Florida Miami, Florida 2010 -Affiliate Clinical Professor of Medicine Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida 2016-Core Faculty Subspecialty Chair, Infectious Diseases Wellington Regional Medical Center Wellington, Florida Internal Medicine Residency, Graduate Medical Education Program 2022 -Designated Institutional Official (DIO) Chief Academic Officer Wellington Regional Medical Center Wellington, Florida ACGME, Internal Medicine Residency Program

MEMBERSHIP IN MEDICAL SOCIETIES

1982 - 88	Associate Member American College of Physicians
1988 - 90	Member American College of Physicians
1988 - 91 1990 - 96	Associate Member Infectious Disease Society of America Member American Society of Internal Medicine
1991-	Fellow American College of Physicians
2009 -	Member Infectious Disease Society of America
2009 -	Member HIVMA – HIV Medical Association
1991 -	Member American Society of Microbiology
1993 - 98	Member Florida Society of Infectious Diseases
1999 - 03	Member American Medical Directors Association
2003- 07	Member American Academy HIV Treating Physicians
2014 -	Member Palm Beach County Medical Society
2020 -	Member Florida Medical Society
2020 -	Fellow Infectious Diseases Society of America

HOSPITAL AND ADMINISTRATIVE APPOINTMENTS

Coronary Care Unit Committee 1984-85 Pennsylvania Hospital Coordinator 1984-85 The University of Pennsylvania School of Medicine Clinical Clerkship, Pennsylvania Hospital Quality Assurance Committee 1988-89 The Lower Bucks Hospital Bristol, Pennsylvania Morbidity and Mortality Committee 1988-1989 Memorial Hospital of Burlington County Mount Holly, New Jersey 1990-2008 Chairman Infection Control Committee Wellington Regional Medical Center West Palm Beach, Florida 1900-2008 Chairman Pharmacy and Therapeutics Committee Wellington Regional Medical Center West Palm Beach, Florida 1991-2015 Chairman Infection Prevention Committee JFK Medical Center West Palm Beach, Florida 1992 - 2010 Chairman Infection Control Committee Palms West Hospital Loxahatchee, Florida Secretary/Treasurer Medical Staff 1993-94 Wellington Regional Medical Center Wellington, Florida Member, Board of Governors 1993-98 Wellington Regional Medical Center Wellington, Florida Secretary/Treasurer Medical Staff 1994-95 JFK Medical Center West Palm Beach, Florida 4

1995-2003	Director, Infectious Diseases IHS of West Palm Beach West Palm Beach, Florida
1996-98	Chairman, Credentials Committee JFK Medical Center West Palm Beach, Florida
1998-2002	Member, Quality Leadership Process JFK Medical Center West Palm Beach, Florida
1998- 2011	Member, Continuing Medical Education Committee JFK Medical Center West Palm Beach, Florida
1998 – 2003	Member Board of Trustees, JFK Medical Center West Palm Beach, Florida
1998 - 2003	Member, Medical Staff Bylaws Committee JFK Medical Center West Palm Beach, Florida
1998 - 2000	President Elect JFK Medical Center West Palm Beach, Florida
2009 - 2015	Member Cubist National Speakers Bureau
2009 - 2015	Member Sanofi-Pasteur National Speakers Bureau
2000 – 03	Member Board of Trustees, Hospice of Palm Beach County West Palm Beach, Florida
2001-	Member National Biodefense Committee John Bartlett, MD, Chairperson
2000 – 02	Chief of Medical Staff JFK Medical Center West Palm Beach, Florida

2006 – 10	Chief, Division of Infectious Diseases JFK Medical Center West Palm Beach, Florida
2008 - 15	Member, Research Committee JFK Medical Center West Palm Beach, Florida
2008	Member, Peer Review Committee JFK Medical Center
2009-2010	West Palm Beach, Florida Member, Board of Trustees JFK Medical Center West Palm Beach, Florida
2010 - 12	Vice Chairman Board of Trustees JFK Medical Center West Palm Beach, Florida
2010 -	Member MKSAP (medical Knowledge Self Assessment) Editions16, 17, 18, 19 Infectious Diseases American College of Physicians Philadelphia, Pennsylvania
2012 - 2015	Chairman Board of Trustees JFK Medical Center West Palm Beach, Florida
2015 -	Member Research Committee Wellington Regional Medical Center
2015 -	Member, Board of Directors Palm Beach County Medical Society Palm Beach County, Florida
2015 -	President, Board of Directors Casa 214 Condominium Association Palm Beach, Florida

Infection Control and Prevention
Wellington Regional Medical Center
Palm Beach County, Florida

2016 - 2018 Chairman

2016 - 2018	Chairman Antibiotic Stewardship Program Wellington Regional Medical Center Palm Beach County, Florida
2016-2017	Treasurer Palm Beach County, Florida, Medical Society
2017-2018	Secretary Palm Beach County, Florida, Medical Society
2018- 2019	1 st Vice President Palm Beach County, Florida, Medical Society
2019-2020	President Elect Palm Beach County, Florida, Medical Society
2020-2021	President Palm Beach County, Florida, Medical Society
2021 -	Chairman, Infection Control and Prevention Committee Wellington Regional Medical Center
2021	Chairman, Clinical Competency Committee Internal Medicine Residency Program Wellington Regional Medical Center
2022 -	Chairman, Medical Education Committee Palm Beach County Medical Society, Florida

MEDICAL JOURNAL EDITORIAL BOARDS

2015 - Editorialist The Merck Manual Website

2011 - Academic Editor
Editorial Board
Case Reports, Infectious Diseases

2015 - Editorial Board Infectious Diseases in Clinical Practice

2021 - Editorial Board American Journal of Medicine

MEDICAL JOURNAL REVIEWER

1991-	Annals of Internal Medicine
2002-	Lancet
2007-	Journal of Medical Case Reviews
2007-	Lab Medicine
2007-	Faculty Medicine 1000
2008 -	Formulary
2008 -	Geriatrics
2009 -	Infectious Diseases in Clinical Practice
2009 -	Lancet: Infectious Diseases
2011 -	Infections and Drug Resistance
2011 -	Case reports in Infectious Diseases
2011 -	Clinical Infectious Diseases
2012 -	Expert Opinion on Pharmacotherapy
2012 -	Bio-Medical Central, Infectious Diseases
2013 -	Journal of HIV and AIDS Research
2014 -	Cardiology
2015 -	Current HIV Research
2016 -	American Journal of Medicine
2016 -	The Open Aids Journal
2018 -	Current Opinion in Gynecology and Obstetrics
2021 -	Open Forum Infectious Diseases
2022 -	BMJ Best Practice
2022 -	Infection
8	

AWARDS AND HONORS

1981	Alpha Omega Alpha National Medical Honor Society The Medical College of Pennsylvania
1980	Marvin N. Solomon Award for Excellence Department of Pathology The Medical College of Pennsylvania
1980	Kurt Pauker Award for Excellence Department of Microbiology The Medical College of Pennsylvania
1980	National Institute of Health Research Fellowship Award Lymphocyte Studies The Medical College of Pennsylvania
1982	Award for Excellence Department of Anesthesiology The Medical College of Pennsylvania
1982	Elected into Who's Who in American Colleges and Universities
1987	Best Research Poster Award Science Day The Medical College of Pennsylvania
1997-99	Best Doctors in South Florida Infectious Diseases Miami Magazine
2000	Best Doctors in Florida Infectious Diseases Castle and Connally
2002	Best Medical Presentations JFK Medical Center, CME Committee
2002	Apollo Award for Service to the Community Palm Beach County Medical Society
2003	Drexel University College of Medicine Deans' Distinguished Achievement Award

2003	Top Doctors Recognition Infectious Diseases Consumer's Guide to Top Doctors
2006	Selected Top Doctor Infectious Diseases Gold Coast Magazine, South Florida
2007	Selected Top Doctor Infectious Diseases The Palm Beacher Magazine, South Florida
2008	Selected Top Doctor New York Times, Florida Edition
2008	Selected Top Doctor Infectious Diseases The Palm Beacher, and Boca Life Magazines, South Florida
2008	Medical Achievement Award Comprehensive AIDS Program Palm Beach County, Florida
2009	Selected Top Doctor Infectious Diseases Miami Herald Newspaper Supplement
2009	Selected Top Doctor Infectious Diseases The Palm Beacher, Boca Life Magazines, South Florida
2010	Selected Top Doctor Infectious Diseases Gold Coast Magazine South Florida
2010	Faculty Teaching Award University of Miami-Miller School of Medicine/ Internal Medicine Resident Program JFK Medical Center
2011	Selected Top Doctor Infectious Diseases Boca Life & Gold Coast Magazines South Florida

2012	Selected Top Doctor Infectious Diseases Gold Coast & Boca Life Magazines South Florida
2013	Selected Top Doctor Infectious Diseases Boca Life Magazine South Florida
2013	Faculty Teaching Award University of Miami-Miller School of Medicine Internal Medicine Resident Program JFK Medical Center
2014	Heroes in Medicine Award (Local/National) Palm Beach County Medical Society Services
2014	Selected "Exceptional Physician" Infectious Diseases Palm Beach Illustrated Palm Beach County Medical Society
2015	Selected "Exceptional Physician" Infectious Diseases Palm Beach Illustrated Palm Beach County Medical Society
2015	Excellence in Medicine Award Palm Beach County Medical Society Palm Beach County, Florida
2016	Innovation Award Wellington Regional Medical Center Wellington, Florida
2016	Faculty Attending Teaching Award Internal Medicine Residency Program Wellington Regional Medical Society
2019	Selected 'Top Doctor' Infectious Diseases Palm Beach Illustrated
2019	Selected 'Top Doc', Infectious Diseases The Palm Beacher and Jupiter Magazine
2020	Selected 'Top Doctor' Infectious Diseases Palm Beach Illustrated and Jupiter Magazine

2021	Selected "Top Doctor" Infectious Diseases Palm Beach Illustrated and Jupiter Magazine
2021	Educator of the Year Award Department of Graduate Medical Graduate Education Internal Medicine Residency Program Wellington Regional Medical Program, Wellington, Florida
2022	Selected 'Top Doctor' Infectious Diseases Palm Beach Illustrated Magazine
2022	Lifetime in Medicine Achievement Award Heroes in Medicine Palm Beach County Medical Society Florida
2023	Selected 'Top Doctor' Infectious Diseases Palm Beach Illustrated Magazine
2023	Clinical Preceptor Faculty of the Year Award Wellington Regional Medical Center Edward Via College of Osteopathic Medicine
2024 i	Selected 'Top Doctor'Infectious Diseases Palm Beach Illustrated Magazine

PUBLICATIONS

ARTICLES

- (1) Hesen MT, Ingerman M, Kaufman D, Weiner P, Santoro J, Korzeniowski OK, Boscia J, **Bush LM**, Kaye D and Levison ME. Clinical efficacy of ciprofloxacin therapy for gram-negative bacillary osteomyelitis. Am J Med 1987, 82(4A):262-5
- (2) **Bush LM** and Boscia JA. Disseminated multiple antibiotic resistant gonnococcal infections Needed changes in antimicrobial therapy. Ann Intern Med 1987:107:692-3
- (3) **Bush LM** and Boscia JA. Outbreak of penicillin resistant disseminated gonococcal infection in southeastern Pennsylvania. Weekly Morbidity and Mortality Report 1988
- (4) **Bush LM** and Levison ME. Antibiotic selection and pharmacokinetics in the critically ill. Critical Care Clinics North Am. 1988:4:2, 299-324

13

- (5) **Bush LM,** Boscia JA and Kaye D. Daptomycin (LY146032) for experimental enterococcal endocarditis. Antimicro Agents Chemother 1988:32:877-881
- (6) **Bush LM** and Levison ME. Appropriate selection and use of antimicrobial agents. Clinical Advancements in Treatment of Infections. 1988; 2:5-9
- (7) **Bush LM**, Boscia JA, Wendler M and Kaye D. The in-vitro post antibiotic effect of daptomycin (LY146032) for enterococcal faecalis and methicillin sensitive and resistant staphylococcus aureus. Antimicrob Agents and Chemother.1989; 33: 1198-1201
- (8) **Bush LM,** Cherney CL, Wendler M, Pitsakis PG, Poupard G, Levison ME and Johnson CC. High level resistance among clinical isolates of enterococcus faecium and implication for therapy of enterococcal infections. Ann Intern Med. 1989; 110: 515-20
- (9) Bush LM, Calmon J and Johnson CC. Newer penicillins and beta-lactamase inhibitor antibiotics. Infect Dis Clin North Am. 1989; 3: 571-94
- (10) Levison ME and **Bush LM.** Pharmacodynamics of antimicrobial agents; Bactericidal and post antibiotic effects. Infect Dis Clin North Am. 1989; 3: 416-21.
- (11) **Bush LM**. Diagnosis and management of pelvic actinomycosis. Clin Adv Treat Infec. 1988; 3: 6-7.
- (12) Dinubile MJ, Abornoz A, Stumacher RJ, VanUitert BL, **Bush LM**, Myers A, Nelson SC and Austrian R. Pneumococcal soft tissue infections. J Infec Dis.1991; 163: 897-9
- (13) **Bush LM**, Moonsamy G and Boscia JA. Evaluation of initiating a Hepatitis B vaccination schedule with one vaccine and completing it with another. Vaccine. 1991: 9; 807-9
- (14) **Bush LM** and Abrutyn E. Diagnosis and treatment of infectious diseases in the elderly. Hospimedica. 1991: 9(1);44-49
- (15) **Bush LM**, Calmon J and Johnson CC. Newer penicillin and betalactamase inhibitor antibiotics. Infect Dis Clin North Am. 1995; 9: 653-86
- (16) **Bush LM** and Johnson CC. Penicillin and beta-lactamase inhibitor antibiotics. Infec Dis Clin North Am. 2000;.......

- (17) **Bush** L, Malecki J, Wiersma S, et al. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 2001; 50(41):889-93.
- (18) **Bush LM**, Abrams BH, Beall A and Johnson CC. Index case of fatal inhalation anthrax due to bioterrorism in the United States. N Engl J Med 2001; 345:1610-4.
- (19) Perez MT and **Bush LM**. Rhodococcus brain abscess in an immunocompetent host. Case report and review of the literature. Inf Dis Clin Pract 2004; 12(1):32-37.
- (20) Malecki JM, Kumar S, Johnson BF, Gidley ML, O'Connor TE, Petenbrink J, **Bush** L, Morand J, Perez MT, Pillai S, Crockett L, Blackmore C, Bradford E, Wirtz RA, Barnwell JW, DaSilva AJ, Causer LM, Parise ME. Local Transmission of Plasmodium vivax Malaria---Palm Beach County, Florida, 2003. MMWR Morb Mortal Wkly Rep 2003;52(38):908-911. JAMA 2003; 290:2931-2934.
- (21) Perez MT and **Bush LM**. A case of eosinophilic granulomatous hepatitis. Lab Med 2004; 35(3): 158-166
- (22) Perez MT, Moran J, **Bush LM**, Crankshaw C and Sudduth NC. Hematological laboratory findings in patients of an autochthonous Plasmodium vivax malaria outbreak. Lab Med 2004; 35(7): 420-
- (23) **Bush, LM.** Disposable items help prevent healthcare-acquired infections. Infection Control Today; 2005; 9(3):44-47.
- (24) Perez MT, **Bush LM** and Perdomo T. A woman presenting with rapidly progressive flaccid paralysis. Review of Guillian-Barre Syndrome and infectious etiologic agents. Lab Med. 2006 37(7): 425-428
- (25) Perez MT, **Bush LM** and Perdomo T. A case of submandibular adenopathy. Review of locally acquired filarial infections. Lab .Med 2006;37(10):619-622
- (26) McFee RB, **Bush LM** and Boehm KM. Avian Influenza: Critical considerations and key strategies for the primary care physician .2006. Adv Study Medicine, Johns Hopkins 2006;6(10):431-440
- (27) De Almeida KNF and **Bush LM**. Treatment of community-acquired methicillin-resistant Staphylococcus aureus infection. Letter, Ann Intern Med. 2006; 145(3), 231-232

- (28) Perez MT and **Bush LM**. Balamuthia Encephalitis. Current Infectious Disease Reports Vol 9. Issue 4: 2007; 323-328
- (29) Perez MT and **Bush LM**. Fatal amebic encephalitis caused by Balamuthia mandrillaris In an immunocompetent host.

 A clinical-pathological review of free-living amebae in humans. Ann Diag Pathol. 2007;11(6):427
- (30) **Bush LM**. And therein lies the resistance. Invited Commentary Current Infectious Disease Reports 2008;10(1):1-2
- (31) Perez MT, **Bush LM** and Rodriguez S. Head and neck pain, syncopal episode, abnormal cerebrospinal fluid and hyponatremia in a middle aged woman; Case Studies. Lab Med 2008;39(6):337-340
- (32) Perez MT, Procop GW, Gomez JA, **Bush LM** and Rodriguez S. Nasofacial Entomophthoromycosis: A case report and review. Infec Dis Clin Pract. 2009;17(1):44-47
- (33) **Bush LM**, De Almeida FN and Perez MT. Severe Strongyloidiasis associated with sub-clinical HTLV-1 infection: A Review. Infec Dis Clin Pract. 2009;17(2):84-89
- (34) **Bush LM**, Chaparro-Rojas F and Perez MT. Rhodotorula and Methicillin-Resistant Staphylococcus aureus septic native hip arthritis and osteomyelits. Infec Dis Clin Prac. 2009; 17;397-398
- (35) **Bush LM**, Zad O, Khan Y, Chapparo-Rojas F, Hasan S, Zeltzer J and Perez MT. Polymicrobial Abdominal aortic endograft infection secondry to aortoenteric paraprosthetic erosion. Infec Dis Clin Prac. 2009; 17:374-37.
- (36) **Bush LM** and Perez MT. Merkel cell carcinoma in HIV-Infected patients: More than a Non-AIDS defining cancer? Infec Dis Clin Prac. 2010;18(2):91-96
- (37) Chapparo-Rojas F, Zhang YD, Fernandez J, Perez MT and **Bush** LM. Pericardial Large B-cell lymphoma as a manifestation of HIV Immune Reconstitution Inflammatory Syndrome.Infec Dis Clin Pract 2010; 18:154-158
- (38) **Bush LM**, Palaraj B, Chaparro-Rojas F and Perez MT.

 Disseminated progressive histoplasmosis in and AIDS patient responsive to trimethoprim-sulfamethoxazole. Infec Dis Clin Pract 2010: 18:239-242

- (39) **Bush LM,** Paturi A, Chapparro-Rojas F and Perez MT.

 Mycobacterial prosthetic valve endocarditis. Current Infectious
 Disease Reports 2010;12(4):257-265
- (40) **Bush LM** and Kaye D. Catheter-associated urinary tract infection IDSA guidelines; But why the levofloxacin? Clin Infec Dis 2010;51:479-480
- (41) Palaraj B, Paturi A, Stone RG, Sebenik M, Alvarez H, Perez MT and **Bush LM**. Anaplastic Large T-cell lymphoma associated with an orthopedic metallic implant. J Foot Ankle Surg 2010;49(6):561-564
- (42) The HIV Controller Consortium. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010;6010:1551-1557
- (43) Regatieri A, Abdelwahed Y, Perez MT and **Bush LM**. Testing for Tuberculosis: The roles of tuberculin skin tests and interferon gamma release assays. Lab Med 2011;42:11-16
- Bush LM, Paturi A, Apuri S, Lin P, Alvarez H and Perez MT.
 Burkitt's leukemia / lymphoma as a manifestation of HIV
 immune reconstitution inflammatory syndrome: A case report and
 review of the literature. HIV & AIDS Review 2011;10:26-32
- (45) **Bush LM** and Chaparro-Rojas F. Tuberculosis: So Prevalent, Yet still an elusive diagnosis. Infec Dis Clin Prac 2011;19(2):77-79
- (46) **Bush LM**, Paturi A, Tower AF, Chaparro-Rojas F and Perex MT. Mycobacterium abscessus prosthetic valve endocarditis: Uncommon but still incurable. Infec Dis Clin Prac 2011;19(3):210-212
- (47) **Bush LM,** Talledo-Thais K, Perez MT. Resistant Herpes Simplex Virus and AIDS: A potential diagnostic and therapeutic dilemma. Lab Medicine 2011;42(8):2-7
- (48) **Bush LM**, Chaparro-Rojas F, Okeh V and Etienne J. Cumulative clinical experience from over a decade of use of levofloxacin in urinary tract infections; Critical appraisal and role in therapy. Infection and Drug Resistance. 2011; 4:177-189.
- (49) **Bush LM**. Best alternative to Vancomycin for treatment of serious MRSA infections: Let's just say it. Clin Infec Dis 2011; 53:965-66
- (50) **Bush LM** and Perez MT. The Anthrax Letters 10 Years later. "Lessons Learned". Ann Int Med 2011;156:41-44.

17

- (51) Shaw S and **Bush LM**. Primary effusion lymphoma and HIV: A Review. HIV & AIDS Rev 2011;10:87-90.
- (52) **Bush LM,** Davidson EE, Daugherty J. Bordetella holmesii prosthetic valve endocarditis: A case report and review. Infec Dis Clin Prac. 2012; 20:248-253.
- (53) Price A, Mohan A, **Bush LM**. Acute sinusitis resulting in a craniotomy: An uncommon complication of a common infection. Case Reports in Infectious Diseases. Volume 2012; Article ID 979836.
- McLaren PJ, Ripke S, Pelak K, **Bush LM**, et al. Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Hum Mol Genet 2012; 21:4334-4347.
- (55) **Bush LM**. Fever in a man with a renal infarct. Letter to the Editor N Engl J Med 2013; 368(23):2237
- (56) Garrido D and **Bush LM**. Liver abscess as a complication of laparoscopic gastric banding bariatric surgery. Surg Infec 2013; 14(5):470-472.
- (57) **Bush LM**, Silva C, Perez MT. Ovarian teratoma associated Anti-N-Methyl-D-Aspartate Receptor autoimmune encephalitis. LabMedicine 2013; 44(3):271-277.
- (58) Song Y, Schroeder JR, **Bush LM**. Iatrogenic Cushing's syndrome and secondary adrenal insufficiency related to concomitant triamcinolone and ritonavir administration: A case report and review. JIAPAC 2014;13(6):511-514.
- (59) **Bush LM**, De Almeida KNF, Martin G, Perez MT. Probiotic associated Bifidobacterium septic prosthetic joint arthritis. Infec Dis Clin Prac 2014;22(4): doi: 10.1097/IPC.0b013e318291c88e
- (60) **Bush LM**, Urritia J, Rodriguez E, Perez MT. AIDS associated cardiac lymphoma: A review: Apropos a case report. JIAPAC (accepted for publication, , 2014).
- (61) **Bush LM**, Kaye D. The diminishing value of vancomycin; Is the time approaching to retire vancomycin from clinical use? Infectious Diseases News, July,2014
- (63) **Bush LM**. Case 28-2014: A Man with a Rash, Headache, Fever, Nausea, and Photophobia. NEJM 2014;371(23):2238-2239.
- (64) **Bush LM**, Vijayvargiya P, Perez MT. Neurocysticercosis.presenting as relapsing aseptic meningitis. Infec Dis Clin Prac 2015;23:48-51.

- (65) **Bush LM**, Alrifal A, Perez MT. Listeria Monocytogenes prosthetic joint infection: A review apropos a case report. Infec Dis Clin Prac 2015;23(2):66-69.
- (66) **Bush LM**, Kaye D. Treating MRSA bacteremia and endocarditis: What are the options. Infectious Disease News, July 2015
- (67) **Bush LM**, Natarajan K, Vazquez-Pertejo MT. Review of Lymphomatous Peritonitis. (submitted for publication, Lab Medicine)
- (68) **Bush LM**, Kaye D. Re-thinking antibiotic(s) and duration of treatment of Intra-Abdominal Infections. Infectious Disease News 2016;29:34-35.
- (69) Vijayvargiya P, Marian D, Vazquez-Pertejo MT, **Bush LM**. Unwarranted pneumococcal vaccination in an acute care hospital related to core quality measure initiatives. Infec Dis Clin Prac 2016;24:24-28.
- (70) **Bush LM**, Kaye D. Optimal antibiotic utilization and preservation: Job of a steward, or time for a pilot? Infectious Disease News. 2016;29:36.
- (71) **Bush LM**, Vazquez-Pertejo MT, De Almeida KNF. Halting tuberculous transmission: The challenge of knowing it is there. Infec Dis Clin Prac 2016; 4:245-247.
- (72) **Bush LM**, Vazquez-Pertejo, MT. The unintended deleterious consequences of the 'routine' urinalysis. Am J Med. 2017;130:3-5.
- (73) **Bush LM**, Vazquez-Pertejo, MT, Kaye D. The urinalysis 'trap'. Infectious Diseases News. 2016.
- (74) **Bush LM**, Kaye D. Optimizing antimicrobial stewardship: Job of a steward or time for a pilot? Clin Infec Dis. 2017; 65(9):1595
- (75) **Bush LM**, Kaye D. Sepsis; Is in the eye of the beholder. Infectious Disease News. 2017; 30(10): 30-31.
- (76) Alkiswany D. **Bush LM**. Myroides soft tissue infections: Falling outside of practice guidelines a propos an instructive case. Infect Dis Clin Prac. 2018;26:106-108.,
- (77) **Bush LM**, Vazquez-Pertejo MT. Tick borne illness Lyme Disease. Disease- a-Month. 2018;64(5):195-212.
- (78) McFee R, **Bush LM**, Vazquez-Pertejo MT. Mosquito vectors. Diseasse-a-Month. 2018;64(5):213-221.
- (79) McFee RB, **Bush LM**, Vazquez-Pertejo MT. Selected Mosquito borne illness- Zika. Disease-a-Month. 2018;64(5):235-245.

- (80) **Bush LM**, Kaye D. Anthrax: A disease of herbivores, and the most important bioweapon. Infectious Disease News. April, 2018
- (81) **Bush LM**, Kaye D. Guidelines for managing Community-Acquired Pneumonia in need of re-evaluation. Infectious Disease News, 2018; 31(9):62-63.
- (82) **Bush LM**, Kaye D. Bacteremia: Often leads to misdirection, but sometimes the clue to the source of the infection. Infectious Disease News, 2018; 31(12):32-33.
- (83) **Bush LM**, Kaye. Laboratory Stewardship: A Concept in need of Implementation. Infectious Disease News, 2019;32(6):53-54.
- (84) **Bush**, **LM**, Kaye D. Antibiotic Dogma, Dictums And Myths: Do we still Hold these "truths" to be self-evident? Infectious Disease News, 2019;32(12):48-49.
- 85) **Bush LM**. Letter: Blood culture results before and after antimicrobial administration. Ann Int Med. 2020;172:439-440.
- 86) DeSuza K, **Bush LM**. Empyema necessitans due to methicillin-sensitive *Staphylococcus aureus*: Case Report and Review Infec Dis Clin Pract. 2020;28(3):130-133
- (87) Marinucci V, Chachine EB, **Bush LM**. Invasive fungal sinusitis caused by *Curvularia* in a patient with type 1 diabetes mellitus. *Journal of Pharmacy Practice*. 2022;35:311-316.
- (88) **Bush LM**, Viggiano V, Tayon M, Sama N, Actinomyces long-bone osteomyelitis: Case report and review. *Infec Dis Clin Pract*. 2021;29(5):e272-e277.
- (89) Sobel JD, **Bush LM**, Tunkel AR. Donald Kaye 1931-2020, in Memoriam. Clin Infec Dis. 2021;72:2244-2245.
- (90) Bush LM, Williams J, Stutchin E. Tocilizumab and SARS-CoV-2 (COVID-19): An Evolving Story, The Picture is Clearer. *Infec Dis Clin Prac*. 2021;29:199-201.
- (91) Falsey AR, Sobieszczyk ME, Hirsch I,**Bush, LM**, et al. Phase 3 Safety and Efficacy of AZD1222 (ChAd Ox1 nCoV-19) Vaccine. *N Engl J Med*. 2021;385:2348-2360.
- (92) Sullivan MB, Veresciac A, **Bush LM**. Cytomegalovirus anterior uveitis in an immunocompetent patient: Case Report and Review. *Infec Dis Clin Pract*. 2023;31, No.2.

- (93) **Bush LM**, Williams J. Leuconostoc lactis bacteremia and neutropenic fever: An infrequently encountered vancomycin-resistant gram-positive cocci: A case report and Review. *Infec Dis Clin Pract*. 2023;31(2):e1234.
- (94) Maska E, Trent AJ, De Lemos A, **Bush LM.** Odontogenic manifestations of herpes zoster infection: A case report and review. (Invited article, *Case Reports Clinical Medicine*.2022;11:487-493.
- (95) **Bush LM**, Patel JB, Byrd L, Wilson DD. Meningococcal purpura fulminans following rectal sexual intercourse in mend having sex with men: A case report and Review. *Infec Dis Clin Pract*. 2023;31(4):e1266.
- (96). Fiallo P, Williams T, **Bush LM**. When antimicrobial treatment and prophylaxis collide: A stewardship opportunity. *Hospital Pharmacy*. sagepub.com/journals-permissions DOI: 10.1177/001857872412300792024;0(0).
- (97) **Bush LM**, Nguyen C, Maska E, HIV and Undetectable = Untransmissible (U=U): Decreasing one sexually transmitted infection (STI) while increasing others, A Narrative review. *Infec Dis Clin Pract*.2024;32(4):1-5.
- (98) **Bush LM**, Maaka E. Preparing our future physicians: "We will reap what we sow". *Cureus*. 2024;16(5) e60799 doi:10.779/cureus.60799.
- (99) Vazquez-Pertejo, MT. Konchan C, **Bush LM**. Post-Inflammatory pigmentary alteration (PIPA)-like disorder following COVID-19 vaccination. (2024, submitted for publication, *Case Reports in Medicine*).

PUBLICATIONS - ABSTRACTS

- (1) **Bush LM**, Boscia JA, Kobasa W and Kaye D. LY146032 treatment of experimental enterococcal endocarditis. In: Program and abstracts of the 27th ICAAC, New York, 4 October 7 October 1987, #16
- (2) **Bush LM**, Boscia JA, Pitsakis PG and Kaye D. In vitro post antibiotic effect of LY146032 for enterocci. In: Program and abstracts of the 27th ICAAC, New York 4 October 7 October, 1987. #142
- (3) **Bush LM**, Calmon J, Chereny CL, Wendler M, Pitsakis PG, Poupard G, Levison ME and Johnson CC. High-level penicillin resistant enterococcus faecium and outcome of treatment in experimental endocarditis. In: Program and abstracts of the 28th ICAAC, Los Angelas, 23 October 26 October 1988, #364

- (4) Calmon J, **Bush LM**, Cherney CL, Wendler M and Johnson CC.
 High-level penicillin resistance among strains of enterococcus faecium
 Program andAbstracts of the 28th ICAAC Los Angeles, 23 October-26
 October, 1988 #1323
- (5) Hensen MT, Pitsakis PG, **Bush LM**, May P and Levison ME. Absence of in vitro synergy of vancomycin and trospectomycin vs enterococci. In; Program and Abstracts of the 28th ICAAC, Los Angeles, 23 October-26 October,1988 #132.
- (6) **Bush LM**. Moonsamy G and Boscia JA, Evaluation of initiating a hepatitis vaccination schedule with one vaccine and completing it with another. Hepatology 1989:10:689
- (7) Kumar S, Malecki JM and **Bush LM**. Emerging infectious diseases: Introduced malaria. Prevention US., San Francisco 1998
- (8) **Bush LM**, Burnside A, DeJesus E, Farthling C, Boone G, Hirani A and Hernandez J. Abacavir (ABS), Lamivudine (3TC), and Amprenavir (APV) +/- low dose Ritonavir (RTV),. Potent and well tolerated HAART regimen in therapy naïve subjects. 1St International AIDS Society, Buenos Aries, Argentina July 8, 2001
- (9) Burnside A, **Bush LM**, DeJesus E, Farthling C, and Hernandez J.
 Metabolic changes with addition of Ritonavir to a HAART regimen of
 APV/3TC/ABC in therapy naïve patients. 3rd HIV
 Adverse Effects and Lipodystrohy conference. Athens, Greece, Oct 2001
- 10) L. Bush, R. Novak, N. Bohidar, S. Rawlins, P. Midgette, H. Wilson and R. Zeldin. Comparison of Indinavir Sulfate (IDV) 800 mg and Ritonavir (RTV) 100 mg b.i.d. + 2 NRTIs vs Nelfinavir (NFV) 1250 mg b.i.d. + 2 NRTIs in HIV-1 infected individuals who have failed or are intolerant to an NNRTI- containing regimen. [Merck Protocol 112] 42ndICAASan Diego 2002.
- M. Sension, Y. Shen, L. Bush, T, Zauli, P. Lopez-Guillen, S. Marrero de Leon, R. Rode, F. McMillan, M. Luo and R. Tressler for The Plato Study Group. Gastrointestinal Tolerability after PI/NNRTI Substitution with Lopinavir/ritonavir. 43rd ICAAC, Chicago 2003.
- (12) Ward, D., **Bush**, L., Thiry, A., Guo, T., Parks, D., Jemsek, J., Jefferson, T., and Thal, G. Atazanavir/Ritonavir (ATV/r) and Efavirenz(EFV) NRTI-sparing regimens in treatment naïve adults. ICAAC, Sept. 2006, #H-1057

- (13) File T, **Bush L**, Desanto J, Markowitz A, Merrick B, Pullman J and Topkis R. Results of a phase 2 study comparing two doses of Radezolid to Linezolid in Adult outpatients with uncomplicated skin and skin structure infections (uSSSI). ICAAC/IDSA, Oct. 2008)
- Urritia G, Rodriguez E, **Bush LM**, Peret MT. Cardiac Lymphoma and AIDS Palm Beach County Medical Society Symposium, Oct. 2013.
- (15) Dayanand S, Avalos D, **Bush LM**. Vibrio vulnificus septic shock and alcalculous cholecystitis in a cirrhotic man. Palm Beach County Medical Society Symposium, Oct, 2013.
- (16) Dayanand S, Martinez J, **Bush LM**. B-Cell lymphoma masquerading as cavernous sinus syndrome. ACP meeting, Orlando, Florida 2013.
- Vijayvargiya P, **Bush LM**, Perez MT. Neurocysticercosis.presenting as relapsing aseptic meningitis. Florida Chapter ACP meeitng, Ft. Lauderdale, Florida, Aug, 2014.
- Vijayvargiya P, Hayes E, **Bush LM**. When cure becomes the disease:
 Disseminated BCG following bladder carcinoma therapy. Palm Beach
 Medical Society, Future of Medicine, Oct, 2014
- (19) Dayanand S, Dayanand P, Martinez J, and **Bush LM**. B Cell lymphoma masquerading as cavernous sinus syndrome. Palm Beach Medical Society, Future of Medicine, Oct., 2014
- (20) Vijayvargiya P, Porter J, **Bush LM**. Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia: A Meta-Analysis. IDSA, October 2015
- Vijayvargiya P, Marian D, **Bush LM**. Unwarranted pneumococcal vaccination in an acute care hospital related to core quality measure initiatives. IDSA, October 2015
- (21) Panara P, DeBay A, **Bush LM**, Vazquez-Pertejo M. Lucero S. Kaposi Sarcoma: a manifestation of AIDS-ewlated immune reconstitution inflammatory syndrome. Palm Beach County Medical Society, Future of Medicine, Sept, 2016
- (22) Romanelli M, Dawound S, Rashid U, Kazmi R, **Bush LM**.

 Neuropsychiatric adverse effects of Oseltamivir. Palm Beach County Medical Society, Future of Medicine, 2019
- (23) Cay E, Alishaev Z, **Bush LM**, Vazquez-Pertejo MT. Coccidioides meningitis in an immunocompetent patient. 2020, Nova Southeastern University School of Medicine poster presentation symposium.

- (24). Johnson G, Konchan C, **Bush LM**. Pachymeningitis Secondary to an Unclassified Vasculitis. Palm Beach County Medical Society, Academic Presentation Day, April 2021.
- (25). Konchan C, **Bush LM**, Vazquez-Pertejo MT. Cuteneous Post-Inflammatory Pigmentary Alteration (PIPA)-Like Disorder Following mRNA COVID-19 Vaccination. (accepted) Palm Beach County Medical Society, Academic Presentation Day, September 2022.
- (26). Fiallo P, **Bush LM.**When Antimicrobial Treatment and Prophylaxis Collide:
 A Stewardship Opportunity
 Palm Beach County Medical Society Med. Ed. Conf. October 2023
- (27) Sargin P, Avci B, Perez R, **Bush LM**. Leukemia Cutis, Atypical Presentation of Acute Myeloid Leukemia
 Palm Beach County Medical Society Med. Ed. Conf. October 2023

BOOK CHAPTERS

- (1) Levison ME and **Bush LM**. Peritonitis and other Intra-Abdominal Infections. In: Mandell GL, Douglas Jr. RG and Bennett JE. (eds).

 Principles and Practice of Infectious Diseases 3rd ed. P,636-689.

 1989, Churchill Livingston New York.
- (2) **Bush LM** and Kaye D. The Epidemiology and Pathogenesis of Infectious Diseases. In: *The Merck Manual of Geriatrics*. 1st ed. 1990. p.883-893. Merck, Sharpe and Dhome, West Point, PA.
- (3) **Bush LM** and Johnson CC. Clinical Syndrome and Diagnosis of Infective Endocarditis. In: Kaye, D(ed.) *Infective Endocarditis* 2nd ed. 1991 Raven Press, New York, NY.
- (4) Levison ME and **Bush LM**. Peritonitis and Other Intra-Abdominal Infections. In: Mandell GL, Bennett JE and Dolin R (eds). *Principles and Practice of Infectious Diseases*. 4th ed. 1995: p.705-740. Churchill Livingston, New York
- (5) Levison ME and **Bush LM.** Peritonitis and Other Intra-Abdominal Infections. In: Mandell GL, Bennett JE and Dolin R (eds). Principles and Practice of Infectious Diseases. 5th ed. 2000: p.821-856. Churchill Livingston, New York.

- (6) Levison ME and **Bush LM**. Peritonitis and Intra-Abdominal abscesses. In: Mandell GL, Bennett JE and Dolin R (eds).

 Principles and Practice of Infectious Diseases. 6th ed. 2005: p. 927-951. Elsevir, Churchill Livingston, Philadelphia.
- (7) **Bush LM** and Perez MT. Anthrax. In: McFee RB and Leikin JB (eds.). *Toxico-Bioterrorism*. Chapter 39: 333-343. 1st ed. 2007. McGraw-Hill, New York.
- (8) Levison ME and **Bush LM**. Peritonitis and Intra-Abdominal abscesses. In: Mandell GL, Bennett JE and Dolin R (eds).

 Principles and Practice of Infectious Diseases. 7th ed. 2010: Chap 71 p.1011-1034. Elsevier, Churchill Livingston, Philadelphia.
- (9) **Bush LM** and Perez MT. Gram Positive Bacilli. *Merck Manual of Diagnostics and Therapuetics*. 19th ed., 2011
- (10) **Bush LM**, Chaparro-Rojas F and Perez MT. Gram Positive Cocci. Merck Manual of Diagnostics and Therapuetics. 19th ed., 2011.
- (11) Tunkel A, Fekete T, Block K, Brown P, **Bush LM**, Frank M, Kaye K, Lopez F and Reboli A. Medical Knowledge Self-Assessment Program (MKSAP) 16, Infectious Diseases. 2012, American College of Physicians, Philadelphia, Pa
- (12) **Bush LM** and Perez MT. Gram Positive Bacilli. *Merck Manual of Diagnostics and Therapuetics*. 20th ed., 2013, 2014, 2015, 2016, 2017, 2019, 2020, 2021, 2022, 2023. 2024
- (13) **Bush LM**, and Perez MT. Gram Positive Cocci. *Merck Manual of Diagnostics and Therapuetics*. 20th ed.,
 2013, 2014, 2015, 2016, 2017, 2019, 2020, 2021, 2022, 2023, 2024
- (14) **Bush LM** and Perez MT. Gram Negative Bacilli. *Merck Manual of Diagnostics and Therapuetics*. 20th ed.,
 2014, 2015, 2016, 2017, 2019, 2020, 2021, 2022, 2023, 2024
- (15) **Bush LM** and Perez, MT. Nisseriaciae. *Merck Manual of Diagnostics and Therapuetics*. 20th ed., 2014.2015, 2016, 2017, 2019, 2020, 2021, 2022. 2024
- (16) **Bush LM** and Perez, MT. Spirochetes. *Merck Manual of Diagnostics and Therapuetics*. 20th ed., 2014, 2015, 2016, 2017, 2019, 2020, 2021, 2022, 2023, 2024

- (17) Levison ME and **Bush LM**. Peritonitis and Intra-Abdominal abscesses. In: Mandell GL, Bennett JE and Dolin R (eds).

 Principles and Practice of Infectious Diseases. 8th ed. 2014: Chap 76 p.935-959. Elsevier, Churchill Livingston, Philadelphia.
- (18) Tunkel A, Block K, Brown P, **Bush LM**, Frank M,
 Lopez F, Choi C, Dembry L, Lopez F, and Reboli A.

 Medical Knowledge Self-Assessment Program (MKSAP) 17, Infectious
 Diseases 2015, AmericanCollege of Physicians, Philadelphia, Pa
- (19) **Bush LM** and Perez, MT. Bacterial Infections: Overview. *Merck Manual of Home Edition.* 20th ed., 2014, 2016, 2018, 2019, 2020,2021, 2022, 2023
- (20) **Bush LM**, Vazquez-Pertejo MT. Anaerobic Bacteria. *Merck Manual of Diagnostics and Therapuetics*. 2017, 2019. 2020, 2021, 2022, 2023, 2024
- (21) **Bush LM**, Vazquez-Pertejo MT. Biology of Infectious Diseases. *Merck Manual of Diagnostics and Therapuetics*, 2019, 2020, 2021, 2022, 2024
- (23) Brown P, **Bush LM**, Block K, Frank M, Lopez F, Choi C, Dembry L, Lopez F, et al. *Medical Knowledge Self- Assessment Program (MKSAP) Infectious Diseases 2018*, American College of Physicians, Philadelphia, Pa
- (24) **Bush LM** and Levison ME. Peritonitis and Intra-Abdominal abscesses. In: Mandell GL, Bennett JE and Dolin R (eds).

 Principles and Practice of Infectious Diseases. 9th ed. 2019; Chapter 74 p.1009-1036. Elsevier, Churchill Livingston, Philadelphia.
- (25) Brown P, **Bush LM**, Block K, Lopez F, Vazquez J, Dembry L, et al. Medical Knowledge self-Assessment Program (MKSAP) 19, Infectious Diseases, 2021, American College of Physicians, Philadelphia, Pa
- (26) **Bush LM** and Levison ME. Peritonitis and Intra-Abdominal abscesses. In: Mandell GL, Bennett JE and Dolin R (eds). *Principles and Practice of Infectious Diseases*. 10th ed. 2023; Chapter 76 Elsevier, Churchill Livingston, Philadelphia (in publication).
- (27) Vazquez-Pertejo MT, **Bush LM**. Laboratoy Diagnosis of Infectious Disease. *Merck Manual of Diagnostics and Therapeutics*. 2024

INVITED SCHOLARLY PRESENTATIONS (recent partial list)

Travel Medicine Update Boca Raton Regional Hospital, Annual Internal Medicine Conference March, 2017

Sepsis is In the Eye of the Beholder JFK Medical Center, Medical Grand Rounds Atlantis, Fl September 2018

Update on Sepsis – Critical Care Society Guidelines Palm Beach County Emergency Medical Services October, 2018

Antibiotic and Laboratory Stewardship: Making it Work Department of Infectious Diseases Warren Alpert Medical School Brown University, Providence, RI. November, 2018

Microbe Hunters: The Anthrax Bioterrorism Attacks 2001 Warren Alpert Medical School Class Brown University, Providence, RI November, 2018

Antibiotics and Sepsis Florida Society of Hospital Pharmacists Palm Beach Atlantic University West Palm Beach, Fl February, 2019

Update on Immunizations JFK Medical Center, Medical Grand Rounds Atlantis, Fl March, 2019

Vaccines; Past, Present, and Future Florida Society of Hospital Pharmacists Palm Beach Atlantic University West Palm Beach, Fl July,2019

Travel Medicine; Before, During, and After the Trip Florida Chapter, American College of Physicians Fort Lauderdale, Fl September, 2019

Anthrax and Bioterrorism

Mayo Clinic Hospital Rochester, MN October, 2019

The Vaccine Crisis; Prepare for Back to the Future Boca Raton Regional Hospital, Medical Grand Rounds Boca Raton, Fl November, 2019

Antimicrobials, Laboratory Stewardship, and Sepsis Lankenau Medical Center, Medical Grand Rounds Philadelphia, Pa December 2019

Novel Coronaviruses Boca Raton Regional Hospital, Medical Grand Rounds Boca Raton, Florida March, 2020

COVID-19; Lessons Learned and How we are Evolving Florida Medical Society, Annual Meeting Orlando, Fl June, 2020

COVID-19 and What You Need to Know Palm Beach County Mensa Society West Palm Beach, Fl September, 2020

Understanding CIVID-19, Pathogen, Host, Environment League of Women Voters Palm Beach County, Fl November, 2020

Controversies Surrounding COVID-19; Facts and Myths Florida Medical Society, Council on Medical Education Tallahassee, Fl, December 2020

COVID-19 Vaccines: Where are we Know? Town Hall Presentation with Congresswoman Lois Frankel Palm Beach County, Fl December, 2020

COVID-19 and the Landscape of Vaccines Internal Medicine Resident Conference Palm Beach County Regional Campus, JFK Medical Center Atlantis, Fl, December, 2020 Update on COVID-19 Vaccines International Women Forum Tampa, Fl January, 2021

COVID-19 Vaccine: Where are we now? Boca Raton Regional Hospital, Medical Grand Rounds Boca Raton, Fl January, 2021

Geographic Infections: United States of America Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Fl January, 2021

Travel Related Infections Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Fl, January, 2021

Agents of Bioterrorism Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Fl January, 2022

COVID-19: Where are we now. Where are we Headed, How to Get There Internal Medicine Residency Program
Wellington Regional Medical Center
Wellington, Fl
January, 2021

SARS-CoV2 (COVID-19): From Basic Science to Immunization Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida, January 2021

COVID-19 Vaccines: Separating Myths from Facts. Space Coast, Florida League of Women Voters February, 2021

Entering GME in the Era of a Pandemic: COVID-19 Graduating Medical School Class Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida, March 2021 Update in Adult Immunization – Vaccine Medicine Internal Medicine Review Conference Boca Raton Regional Hospital, Baptist Health March, 2021

COVID-19 Vaccines: Who, What, When, and How Valencia Retired Physician Organization Boynton Beach, Florida March, 2021

Controversies Surrounding COVID-19 Vaccinations Retired Physicians Lecture Series Palm Beach County Medical Society April, 2021

HIV / AIDS Primer South University Physician Assistant School Class West Palm Beach, Florida May, 2021

COVID-19 Vaccinations 'Virtual Town Hall' Palm Beach County Mayor and Commissioners June, 2021

All About COVID-19 Vaccination Jewish Federation of South Palm Beach County Palm Beach County, Florida June, 2021

COVID-19 Update Escambia County / Santa Rosa County Medical Society Pensacola, Florida July, 2021

New and Newer Antibiotics : How and Why we got Here Baptist, Boca Regional Medical Center August, 2021

Anthrax Bioterrorism 20 Years Later: Lessons Learned and are We Better Prepared?

Medical Grand Rounds

Wellington Regional Medical Center, October 2021

Omicron- COVID-19

Medical Grand Rounds

Boca Raton Regional Hospital, Baptist Health System

December, 2021

Travel Medicine Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida January, 2022

Geographic Medicine Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida January, 2022

Bioterrorism Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida January, 2022

Antibiotic Overuse Internal Medicine Review Conference Boca Raton Regional Hospital, Baptist Health March, 2022

Antimicrobial Therapy: "Past, Present and Hopefully Future" Nova Southeastern University, School of Medicine Medical Grand Rounds March, 2022

The Anthrax Attacks 20 Years Later: Are We Better Prepared? Boca Raton Regional Hospital, Baptist Health April 2022

Antimicrobial Resistance: The Fix is In OUR Hands Baptist – Homestead Medical Center May,2022

The Anthrax Attacks 20 Years Later: Are We Better Prepared? Medical Grand Rounds Mayo Clinic Hospital Rochester, Minnesota May 2022

Antibiotic Stewardship and Laboratory Utilization : Time to Get It Right Medical Grand Rounds HCA East Florida, JFK Medical Center Atlantis, Florida September, 2022

Clostridioides (Clostridium) Difficile Infection : An Update Baptist South Health GI Symposium October 2022

The Antimicrobial Resistance Crisis: How did We Get Here and How Do We Fix It American College of Physicians (ACP) Florida Chapter Conference Fort Lauderdale, Florida October 2022

The Death of Antibiotics - How did this Happen and How do We Recover?
The Future if Medicine Conference
Palm Beach County Medical Society, Florida
March 2023

Emerging and Re-Emerging Infectious Diseases Ebola, Monkey Pox (MPOX), and What's Next? Baptist Medicine Annual Internal Medicine Symposium, March 2023

Vaccines: Its not Just About Covid-19 Palm Beach County Medical Society Medical Education Symposium October 2023

Updates on Clostridium Difficile Infection JFK Medical Center, GME Internal Medicine Progream Palm Beach County, Florida Medical Grand Rounds October 2023

Update on Travel Medicine Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida January, 2024

Geographic Medicine Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Floirida January 2024

Recognizing Class 'A' Agents of Bioterrorism Charles E. Schmidt College of Medicine Florida Atlantic University Boca Raton, Florida January, 2024

<u>CLINICAL RESEARCH - PRINCIPAL INVESTIGATOR</u>

1986	Oral Ciprofloxacin for the Treatment of Gram Negative Bacillary Osteomyelitis (sub-investigator)
1989	The use of Engerix B Hepatitis Vaccine to Complete a series started with Recombivax B Vaccine
1991	Famciclovir therapy for the prevention of post-herpetic neuralgia in acute Herpes Zoster
1997	NNRTI vs Protease Inhibitor Combination for the Treatment of Naïve HIV Patients
1998	Vancomycin Resistant Enterococcal Treatment with a novel antibiotic agent
1998	Open-Label Study with an Injectable mediciation for the treatment of HIV patients with anemia
1999	Protease Inhibitor vs NNRTI in the treatment of HIV Patients who are virologically suppressed
1999	Open Label Treatment with antiretroviral agents in HIV infected patients
1999	Double Blinded Study with treatment of naïve HIV Patients using antiretroviral therapies
1999	Double-Blinded Study comparing the safety and efficacy of two IV antibiotics in the treatment of patients with nosocomial pneumonia
2000	Open- Label, Randomized Study for the Treatment of Suspected or Proven Methicillin Resistant Staphylococcal Infections
2000	Double-Blinded, Randomized Study with a new NRTI plus an NNRTI in Treatment naïve HIV Patients
2001	Protease Inhibitor plus two NRTI vs a Boosted Protease Inhibitor plus two NRTI in NNRTI failing HIV Patients
33	

2001	Pegylated Interferon Treatment in Hepatitis C and HIV Coinfected Patients
2001	A Combination Boosted Protease Inhibitor plus two NRTI's in Virologically Suppressed HIV patients Intolerant to an ART regimen including an NNRTI
2001	Two Different Beta-Lactam/Beta-Lactamase Inhibitor Combination Antimicrobials for the Treatment of Infected Diabetic Foot Ulcers
2001	A Lipopeptide vs an Oxazolidinone Antibiotic for the Treatment of Proven or Suspected Vancomycin Resistant Enterococcal Infections
2001	A boosted PI regimen with two NRTI's vs a novel PI with two NRTI's in patients failing their 1st PI regimen
2001	A new Protease Inhibitor containing regimen along with a new NRTI in HIV treatment failure patients
2002	Linezolid IV/PO vs vancomycin for treatment of soft tissue infections caused by resistant gram positive cocci
2002	Intensification of a failing NRTI containing ART regimen using a third NRTI plus a new nucleotide NRTI drug
2002	Imipenem vs Meropenem for complex skin and soft tissue Infections
2002	Antiretrovial therapy in treatment naïve HIV patients comparing a once a day combination protease inhibitor regimen to that of twice a day dosing along with a novel NRTI compound receiving antiretrovial which includes a protease inhibitor and demonstrating elevations in plasma lipids.
2002	The use of a new Carbapenem parenteral antibiotic for treatment of intra-abdominal infections
2003	Antiretroviral therapy in treatment naïve HIV infected patients using a new nucleotide agent combined with two other once daily medications.

The use of a lipopeptide injectable antimicrobial agent 2003 for the treatment of bacteremia or endocarditis caused by Staphylococcus aureus in patients intolerable to standard treatment regimens. The use of a novel compound for treatment of HIV induced 2003 neuropathic pain. Evaluation of AIDS patients admitted to a hospital for infections 2003 while on T-20 fusion inhibitor therapy. Evaluating the anti- viral efficacy, safety, and effect on serum 2004 lipids of one boosted protease inhibitor with another, each in combination with two NRTI medications, in subjects receiving a NNRTI-containing HAART regimen who are experiencing their first virologic failure The use of a once a day protease inhibitor along with a NNRTI 2004 medication in the treatment of HIV naïve patients. Switching HIV treatment to a protease inhibitor in combination 2004 with two NRTI medications in patients with virologic failure on their first NRTI regimen. Switching HIV treatment to a NNRTI based once a day regimen 2004 in patients virologically suppressed on their first protease inhibitor regimen Use of a new glycopeptide parenteral antibiotic versus standard 2004 care in the treatment of complex soft tissue infections caused by gram-positive organisms. 2004 The use of a new parenteral carbapenem antibiotic versus a quinolone in the treatment of pyelonephritis The use of a new parenteral carbapenem antibiotic versus a beta-2004 lactam/ beta-lactamase inhibitor combination in complex intraabdominal infections The use of a new parenteral carbapenem antibiotic versus standard 2004 therapy in hospital acquired pneumonia Linezolid versus vancomycin therapy in the treatment of hospital 2004 acquired pneumonia caused by methicillin resistant Staphylococcal aureus 2004 Daptomycin versus standard of care treatment in post-operative wound infections

2004 Use of a novel compound in the treatment of severe sepsis. 2004 Linezolid versus standard therapy in complex soft tissue infections caused by gram positive organisms 2005 Study to evaluate the 150L substitution among subjects experiencing virologic failure on a HAART regimen containing Atazanavir Use of an entry inhibitor with two NRTI medications compared 2005 with an NNRTI/NRTI HAART regimen in treatment naïve HIV patients 2005 Comparing one boosted new formulation PI with a fixed combination PI together with a dual NRTI backbone in treatment naïve HIV patients 2005 Phase 4, prospective, open-label, multi-center study of safety, efficacy, and adherence in HIV infected, antiretroviral naïve patients treated with a simple once-daily regimen 2005 Phase 4 evaluation of switching from twice daily AZT and 3TC to a simplified once-daily regimen of co-formulated FTC and TDF in virologically suppressed HIV infected patients taking EFV Phase 3 randomized, investigator blind, multi-center study to 2005 evaluate efficacy and safety of intravenous iclaprim versus linezolid in complicated skin and skin structure infections 2005 A randomized open label study assessing safety, tolerability, and efficacy of aninduction/maintenance treatment strategy including lopinavir/ritonavir plustenofovir and emtricitabine versus efavirenz plus tenofovir and emtricitabinein antiretroviral naïve HIV-1/HCV co-infected subjects A randomized, double blinded, placebo-controlled, multicenter 2005 study exploring the safety, tolerability, and antiviral effect of substituting 600 mg of Racivir (RCV) lamividine (3TC) in HIV infected subjects who have the M184V mutation and are currently failing on a HAART regimen containing lamivudin 2006 Comparison of a new formulation of Kaletra with once daily dosing vs twice daily dosing, both with a NRTI backbone Using a novel topical antiseptic vs betadine in the prevention of 2006 central venous catheter line infections in hospitalized patients.

2006	Phase 2 randomized study of the treatment of antiretroviral treatment-experienced HIV infected subjects with a ritonavir boosted novel integrase inhibitor versus a comparator boosted protease inhibitor both with background ARV medications
2006	Comparison of different boosted Lexiva regimens in treatment experienced HIV/AIDS patients
2006	Multicenter, randomized, double-blind, controlled study of NGX-4010 for the treatment of painful HIV associated neuropathy
2006	A controlled comparison of Eritoran Tetrasodium and placebo in patients with severe sepsis
2006	A pivotal, multicenter, multinational, randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of TAK-242 in adults with severe sepsis
2007	A phase 3 open label multi-center study of the safety of ritonavir boosted GS-9137 administered in combination with other antiretroviral agents for the treatment of infected subjects
2007	A phase 3 multi-center randomized, double blind comparative study to evaluate the safety and efficacy of Ceftaroline vs Vancomycin plus Aztreonam in adult subjects with complicated skin and skin structure infections
2007	A multi-center randomized, double blind comparison study of the safety and efficacy of a once daily dose of Tigecycline vs Ertapenem for the treatment of foot infections in subjects with diabetes
2007	Randomized, double blind parallel group placebo controlled 2 stage study to assess the efficacy and safety of Crofelemer for the treatment of HIV associated diarrhea.
2007	Phase 2, multicenter, randomized, open label, comparative study to evaluate RX-174 vs linezolid in the outpatient treatment of patients with uncomplicated skin and skin structure infections.
2007	Ortivancin for the treatment of complicated soft tissue infections caused by gram-positive cocci organisms including methicillin-resistant Staphylococcus aureus (sub-investigator)
2008	A randomized multi-center study using Ceftaroline intramuscular for the treatment of complicated skin and soft tissue infections.
2008	The use of Ceftaroline given intra-muscularly vs. intravenous linezolid for the treatment of complex skin and soft tissue infections including methicillin resistant Staphylococcal aureus
37	

- 2008 Randomized, open label, study of lopinavir / ritonavir 400/100 mg tablet twice-daily and co-formulated emticitabine / tenofovir 200/300 mg once daily versus lopinavir / ritonavir 400/100 mg twice daily in antiretroviral naïve HIV-1 infected subjects
- Multicenter, randomized, double blind, double dummy, phase 3 study of the safety and efficacy of ritonavir-boosted elvitegravir (EVG/r) versus raltegravir (RAL) each administered with a background regimen in HIV-1 infected, antiretroviral treatment experienced adult
- A phase 3, randomized, double-blind trial of TMC278 25mg daily versus efavirenz 600m daily in combination with a background regimen consisting of 2 nucleoside/nucleotide reverse transcriptase inhibitors in antiretroviral-naïve HIV-1 infected subject
- A phase 2 randomized, double-blinded study of the safety and efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumrate/GS-9350 Versus Atripla (Efavirenz 600mg Emtricitabine 200mg/Tenofovir Disoproxil Fumarate (FTC/TDF) in HIV-1-infected Antiretroviral Treatment-naïve adults
- A phase 2, rrandomized, double-blinded study of the safety and efficacy of GS-9350 boosted Atazanavir (ATV/GS-9350) compared to Ritonovir-boosted Atazanavir(ATV/r) in combination with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC.TDF) in HIV-1 infected, antiretroviral treatment-naïve adults
- A randomized, double-blind, couble dummy, comparative, multicenter study to assess the safety and efficacy of topical Retapamulin ointment 1%, versus oral Linezolid in the treatment of secondarily-infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus
- A randomized, evaluator-blinded, phase 3 study to compare the safety and efficacy of PKT 0796 with Linezolid in the treatment of adults with complicated skin and skin structure infections
- A phase 2 randomized, double-blind, double-dummy, efficacy, safety and tolerability study of IV Sulopenem with switch to oral PF-03709270 compared to Ceftriaxone with step down to amoxicillin-clavulanate potassium (augmentin) in subjects with community acquired pneumonia (CAP) requiring hospitalization.

- A phase 2b, randomized, double blinded, 48 week, multicenter, placebo controlled, dose optimizing study of Ibalizumab plus and optimized background regimen versus placebo plus an optimizing background in treatment experienced patients with HIV-1
- A phase III randomized, double-blind, placebo-controlled multicenter study in adults to determine the safety, efficacy, and immunogenicity of AZD1222, a non-replicating ChAdOx1 Vector Vaccine for the prevention of COVID-19.
- 2020 SPR720-201: A Randomized, Partially Blinded, Placebo- and Comparator-Controlled, Multicenter, Phase 2a, Dose-Ranging, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SPR720 as Compared with Placebo or Standard of Care for the Treatment of Patients with Mycobacterium avium Complex (MAC) pulmonary disease
- A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
- A Randomized, Double-Blind, Placebo-Controlled Phase 3 Efficacy Study of an Ad26.RSV.preF-based Vaccine in the Prevention of RSV-mediated Lower Respiratory Tract Disease in Adults Aged 60 Years and Older.
- A phase IIIB, randomized, controlled, observer-blind study to evaluate safety and immunogenicity of GSK's meningococcal ABCWY vaccine when administered in healthy adolescents and adults, previously primed with meningococcal ACWY vaccine"
- 2021 MK4482-002: A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of MK-4482 in Non-Hospitalized Participants ≥18 Years of Age with COVID
- A randomized controlled study to assess SARS-Cov-2 infection, viral shedding, and subsequent potential transmission in individuals immunized with a Moderna COVID-19 vaccine.
- A Phase III, randomized, open-label,, controlled, multi-center study to evaluate the immune response and safety of both herpes zoster subunit vaccine in healthy adults aged 50 years and older and influenza virus vaccine in healthy adults aged 18 years and older when administered sequentially or co-administered with mRNA-1273 booster vaccination.
- A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine naïve Adults

- 2023 A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune Impairment
- 2023. A Phase 2 Randomized, Open-Label, Active-Controlled Study Evaluating the Safety and Efficacy of an Oral Weekly Regimen of Islatravir in Combination with Lenacapavir in Virologically Suppressed People with HIV



2024 BOARD OF DIRECTORS

September 26, 2024

President
Dawn Davanzo, MD
President-Elect
Andrew Berkman, MD
Vice President
Vicki Norton, MD
Decretary
Ann Thomas, MD
Ireasurer
Josh Gottsegen, MD
mmediate Past President
Martha Rodriguez, MD

lose Arrascue, MD Stephen Babic, MD Shawn Baca, MD Larry Bush, MD Michael Dennis, MD Faustino Gonzalez, MD Catherine Miller, MD Alan B. Pillersdorf, MD Jack Zeltzer, MD Resident Amal Benchakroun, MD Medical Student Goojung Choi

Gazelle Aram, MD

Barbara Sullivan
Information Security & Privacy Coordinator
Legal Office
FL Dept. of Health, Palm Beach County
P.O. Box 29
800 Clematis Street
West Palm Beach, FL 33401

Dear Barbara,

We are pleased to notify you that the Palm Beach County Medical Society Board of Directors voted favorably on September 19, 2024, to recommend Dr. Larry Bush serve as its representative on the Environmental Hearing Control Board within the Florida Department of Health, Palm Beach County.

PBCMS is grateful to Dr. David Shulan for his many years of service on the ECHB and feels confident that Dr. Bush will also serve with dedication and distinction. As an infectious disease specialist, Dr. Bush has a wealth of knowledge and experience and will offer clear guidance on issues relevant to the board's hearings.

Please do not hesitate to contact me should you need any additional information.

All the best,

Kelly Skidnore,/CEO

Palm Beach County Medical Society 3540 Forest Hill Boulevard, Suite 101 West Palm Beach, FL 33406 (561) 433-3940 www.pbcms.org

5. Meetings

a. General or Special Meetings

General meetings of the EAB shall be held no less frequently than once every 60 days. Special meetings may be called by the Chair of the EAB, or in writing by a majority of the members of the Board. Staff shall provide 24-hour written notice to each EAB member for a special meeting.

E. Environmental Control Hearing Board

1. Establishment

There is hereby established an Environmental Control Hearing Board (ECHB).

2. Powers and Duties

The ECHB has the following powers and duties:

- a. to conduct hearings into the merits of alleged violations to Sections promulgated under Chapter 77-616, Special Acts, Laws of Florida, and PBC Ordinance No. 78-5, as amended; and
- b. after due public hearing, to reach a decision setting forth such findings of fact and conclusions of law as are required in view of the issues presented. The decision shall contain an order which may be framed in the manner of a writ of injunction requiring the violator to conform to either or both of the following requirements:
 - to refrain from committing, creating, maintaining, or permitting the violations;
 - to take such affirmative action as the ECHB deems necessary and reasonable under the circumstances to correct such violation;
 - to issue orders imposing civil penalties of up to 500 dollars for each day of violation;
 - to issue subpoenas to command the appearance of any person before a hearing at a specified time and place to be examined as a witness. Such subpoenas may require such person to produce all books, papers, and documents in that person's possession or under that person's control, material to such hearings; and,
 - 5) to administer oaths to any or all persons who are to testify before the ECHB.

3. Qualifications

The ECHB shall be composed of five members. The membership of the ECHB shall consist of one attorney recommended by the PBC Bar Association; one medical doctor recommended by the PBC Medical Society; one engineer recommended by the PBC Chapter of the Florida Engineering Society; and, two citizens at large.

4. Officers

a. Secretary

The Environmental Control Officer shall serve as Secretary of the ECHB.

Staff

The PBCHD shall be the professional staff of the ECHB.

5. General or Special Meetings

General meetings of the ECHB shall be held no less frequently than every 45 days. The ECHB may set the date of future meetings during any meeting. Special meetings may be called by the Chair of the ECHB, or in writing by a majority of the members of the Board. Staff shall provide 24-hour written notice to each ECHB member for a special meeting.

Term Limits

Beginning on or after March 2, 2013, no person shall be appointed or reappointed to this Board for more than three consecutive terms. [Ord. 2014-001]

F. Groundwater and Natural Resources Protection Board

1. Establishment

There is hereby established a Groundwater and Natural Resources Protection Board (GNRPB).

2. Powers and Duties

The GNRPB shall have the following powers and duties:

- a. to hold hearings as necessary to enforce Art. 14, Environmental Standards. ERM may refer alleged violations of Art. 14, Environmental Standards, and applicable Art. 4.B.10, Excavation Uses, Ordinance No. 2003-020, Petroleum Storage Systems, Ordinance No. 2003-021, Petroleum Contamination Cleanup Criteria, Ordinance No. 2004-050, Stormwater Pollution Prevention, Ordinance No. 94-13, Natural Areas, and Ordinance No. 93-3, Water and Irrigation Conservation as amended to the GNRPB, if there has been a failure to correct a violation within the time specified by the Code Inspector, if the violation has been repeated, or is of such a nature that it cannot be corrected; [Ord. 2006-004] [Ord. 2010-022] [Ord. 2017-007]
- b. to adopt rules of procedure for the conduct of hearings;
- to issue subpoenas compelling the presence of persons at Board hearings. Subpoenas may be served by the PBC Sheriff's Department, or other authorized persons consistent with Florida law;

Unified Land Development Code Supplement No. 31 (Printed 08/23)

Article 2 - Application Processes and Procedures